Benha Journal of Applied Sciences (BJAS) **print: ISSN 2356–9751**
Vol. (9) Issue (6) (2024), (53-56) **online: ISSN 2356 –976x**
http://bjas.bu.edu.eg

Serum Vaspin in Vitiligo Patients

Reham H. Emara[1], Shymaa M. Rezk[1], Fatma M. El-Esawy[1] and Yasmin M. AMarei[2]
[1]Dermatology, Venerology and Andrology Department, Faculty of Medicine, Benha University, Benha, Egypt
[2]Medical Chemistry and Molecular biology Department, Faculty of Medicine, Benha University, Benha, Egypt
E-Mail: rehamhamdyz123@gmail.com

Abstract

Background: Vitiligo is recognized as a systemic depigmenting skin illness with a complex etiology. Its effects extend beyond the skin and into the body, causing metabolic irregularities such glucose and lipid abnormalities. Many nations throughout the globe are experiencing pandemic levels of obesity. Excess white adipose tissue causes systemic and chronic inflammation since it is an active endocrine organ. Adipocytes and macrophages, which are cells of adipose tissue, release adipocytokines, which induce and sustain this inflammation. Both vaspin and omentin are adipocytokines that have just recently been identified. The purpose of this piece is to provide a synopsis of the function of vaspin proteins in psoriasis and vitiligo. It provides a summary of the vaspin function and how it relates to the severity of vitiligo in patients. In summary: Vaspin, a serine protease inhibitor produced from visceral adipose tissue, has several functions in skin disorders. Changes in its expression levels may help with diagnosis and prognosis in vitiligo and psoriasis.

Key words: Vitiligo, Vaspin, Pathogenesis, Clinical pics, Gene polymorphism, these are the keywords.

Introduction

Vitiligo is a pigmentary condition that affects the skin and mucous membranes. It is marked by patches and macules that are depigmented at their edges [1]. The immune system mistakenly attacks the skin's melanocytes, leading to vitiligo, a condition characterized by gradual loss of pigmentation [2].

Vitiligo has a complicated pathophysiology and is a polygenic condition involving several factors. There have been many proposed explanations for this condition, including oxidative stress, neurological processes, viral infections, melanocyte development and faulty adhesion, and autoimmunity [3]. Among these, the autoimmune hypothesis is now widely believed to be the most plausible.

Vaspin, an inhibitor of serine protease produced from visceral adipose tissue (also called Serpin A12), is a 47-kDa protein of 415 amino acids. It is a member of the serpin family. Otsuka Long-Evans Tokushima's visceral white adipose tissue was the first to show strong expression of vaspin in 2005. At the apex of obesity and insulin plasma levels, which occurs at 30 weeks of age in fatty rats, [5].

1.Review of literature

Vitiligo

Vitiligo white macules and patches appear on the body as a consequence of this acquired pigmentary skin condition, which is caused by the lack of pigmentary cells from the epidermis.Thyroid problems are the most prevalent autoimmune illness linked with the syndrome. In spite of the fact that vitiligo's exact cause is a mystery, some hypotheses attempt to explain its pathogenesis[6, 7].

Public health

Worldwide, vitiligo affects an estimated half a percent to two percent of the population, affecting both children and adults. It is the most prevalent depigmenting skin condition. In 1977, one of the first and biggest epidemiological surveys ever recorded was carried out on the Danish island of Bornholm [7]. It was found that 0.38 percent of the population suffered from vitiligo. Everyone, regardless of race or ethnicity, and all skin types may have vitiligo [8].

Why Vitiligo Occurs and How It Develops

Vitiligo has a complicated pathophysiology and is often referred to as a multifactorial polygenic condition. Both hereditary and non-hereditary variables are often linked to it. The specific cause is unclear, however several hypotheses have been advanced about its pathology. Commonly accepted concepts state that vitiligo skin is characterized by a loss of melanocytes or their complete absence. Progressive reductions in melanocytes are the most common outcome of destruction. Cytotoxic, autoimmune, intrinsic, neurological, and oxidant-antioxidant pathways are some of the hypothesized causes of melanocyte death [9].

Neuronal theory and hereditary variables

Both segmental vitiligo (SV) and non-segmental vitiligo (NSV) seem to be the result of a multi-stage process that begins with an injury, either internal or external, and continues with the production of neuropeptides and proinflammatory cytokines, followed by vascular dilatation and an immunological response [10].

Although there is some evidence that vitiligo runs in families, the risk is not always present. An elevated relative risk of vitiligo of seven to ten times is seen in first-degree relatives of around 20% of vitiligo patients. The significance of extra random or environmental variables in the development of vitiligo is shown by the 23% concordance rate in monozygotic twins [11].

Roughly fifty distinct genetic loci have been identified in Chinese and white European ancestry individuals as conferring vitiligo risk, according to large-scale genome-wide association studies [12]. Several autoimmune diseases, including rheumatoid arthritis, thyroid disease, and type 1 diabetes, share several loci that are involved in the innate and adaptive immune systems. The rate-limiting stages of melanin production are catalyzed by the enzyme tyrosinase, which is encoded by the TYR gene. Generalized vitiligo is characterized by tyrosinase, an autoantigen [13].

Free Radical Damage

Free Radical Damage According to studies looking into the causes of vitiligo, oxidative stress might be the first step in the death of melanocytes. Melanocytes from vitiligo patients are more easily damaged by oxidative stress and are harder to cultivate in vitro than healthy controls, according to research [14].

Vitiligo immunity

When it comes to vitiligo, innate immunity acts as a link between adaptive immunity and oxidative stress. In the early stages of vitiligo, innate immune cells are activated by stress signals detected by melanocytes and maybe keratinocytes, which may be generated either externally or internally [15]. Variants affecting the innate immune system regulator NALP1 have been linked to an increased risk of vitiligo. The skin of vitiligo patients includes genomic expression study that has shown an unusually high level of innate immunity in the area around melanocytes, especially natural killer cells [16].

Flexibility in Immunity The development of vitiligo is influenced by immune system abnormalities that are either humoral or cell-mediated. Patients with vitiligo have previously had antibodies detected in their serum against cytoplasmic and surface melanocyte antigens. Through complement-mediated lysis and antibody-dependent cellular cytotoxicity, these antibodies may cause the death of cultured melanocytes [17].

Classification

1-Acrofacial, mucosal, common, universal, and mixed vitiligos are all part of the non-segmental vitiligo (NSV) category, which also includes unusual variants [18].

One, two, or even more segments may be affected by 2-Segmental Vitiligo (SV). One or more white macules on one side of the body, often respecting the body midline, are characteristic of the most frequent variety, known as unisegmental, which also has quick onset, involvement of body hair (leukotrichia), and other symptoms. Bilateral segmental distribution, affecting two or more segments at once or not at all, is a less frequent occurrence [19].

3-Vitiligo that cannot be classified or identified There are two kinds of this condition: focal, in which only one mucosa is damaged, and mucosal, in which the lesion spreads to other areas [20].

The Vaspin

A member of the serpin family of proteins, Vaspin (visceral adipose tissue-derived serine protease inhibitor) has 415 amino acids and a molecular weight of 47 kDa [21].

Evidence suggests that vaspin expression in visceral adipose tissue declines with increasing bulk and that vaspin expression in subcutaneous adipose tissue is adipocyte-specific in abdominal adipose tissue. Importantly, plasma vaspin levels are considerably greater in women than in males, indicating a sexual dimorphism in circulating vaspin [22].

Research on vaspin's anti-inflammatory properties on vascular cells has been conducted. Take HUVECs as an example. Vaspin seems to have no impact on basal morphology and TNF-α-induced morphological damage. This is because it merely inhibited TNF-α-induced Akt phosphorylation to a small extent, without reducing the TNF-α activation of JNK, p38, and NF-kB signaling. Additionally, it did not decrease the expression of molecules related to inflammation and/or endothelial cell dysfunction, such as VCAM-1, ICAM-1, and MCP-1.

Vaspinoid function in psoriasis

Psoriasis' metabolically induced inflammation increases the risk of cardiovascular disease (CVD), hypercholesterolemia, diabetes mellitus (DM), and other cardiometabolic illnesses. Myocardial infarction and thromboembolic events, which may be deadly, should be closely monitored in this patient population [24].

Because of its involvement in obesity and metabolic diseases, research found a strong association between vaspin level and body mass index (BMI) of psoriatic patients. The fact that vaspin has a favorable correlation with lipid parameters may indicate that it modulates the formation of CMDs in psoriatic skin. There may be a connection between metabolic problems in psoriasis and its lowered serum level [25].

The function of vaspin in hair loss

The serum vaspin levels of vitiligo patients were much lower. In isolated adipocytes, vaspin reduces the pro-inflammatory cytokine response caused by IL-1 and inhibits tumor necrosis factor-induced intercellular adhesion molecule-1 expression, reactive oxygen species production, nuclear factor kappa B activation, and cytokine-driven inflammation in 3t3-L1 adipocytes. In support of vaspin's anti-inflammatory capabilities, there is evidence of a relationship between the two substances and the inflammatory markers that were tested [26].

Inflammation is a factor in the development of vitiligo and associated complications, according to recent studies. Effective therapy of vitiligo and

associated illnesses is achieved by blocking the inflammatory interferon-chemokine signaling pathway with Janus kinase inhibitors such ruxolitinib, baricitinib, and tofacitinib [27].

There is a shared genetic underpinning for heightened autoimmune and inflammation between vitiligo and psoriasis. Genetic susceptibility to several autoimmune illnesses has been increasingly supported by genome-wide association studies [28]. Patients with widespread vitiligo may be at increased risk for developing psoriasis due to variations in infammasome-related genetic sequences [29]. Vitiligo and psoriasis are two skin conditions that exhibit inflammasome markers [30].

Some have speculated that the fact that some people have both vitiligo and psoriasis, or that the psoriatic plaques are limited to vitiligo patches, may be the result of pure coincidence. Patients with psoriasis were 2.29 times more likely to have vitiligo than controls, while patients with vitiligo were 2.29 times more likely to have psoriasis, according to meta-analyses [31].

In summary: The vaspin protein, which is produced from visceral adipose tissue and acts as a serine protease inhibitor, has several functions in skin disorders. Changes in its expression levels in vitiligo might help with diagnosis and prognosis.

References

[1] H, Mumtaz S, Anis A, Akhtar M, Rubab A, Zafar N. Niazi, and Fatima T.: Efficacy of Tacrolimus Versus Clobetasol in the Treatment of Vitiligo. Cureus, vol:12(12). 2020

[2] K, Boniface J, Seneschal M, Picardo and A. Taïeb: Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. Clinical reviews in allergy and immunology, vol: 54(1),pp. 52-67. 2018

[3] G, Benincasa G, Di Spigna C, Cappelli R, Di Francia M, Ottaiano M. Sansone and L. Postiglione: High incidence of MTHFR, CBS, and MTRR polymorphisms in vitiligo patients. Preliminary report in a retrospective study. Eur Rev Med Pharmacol Sci, vol:23(2), pp.471-478. 2019

[4] G., Iannella A., Greco D., Didona B., Didona G., Granata A., Manno & G.Magliulo: Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmunity reviews, vol:15(4),pp. 335-343.2016

[5] P, Kurowska E, Mlyczyńska M, M, Dawid Jurek D, Klimczyk J, Dupont & A. Rak: Vaspin (SERPINA12) expression and function in endocrine cells. Cells, vol:10(7), pp.1710. 2021

[6] M .Weiss,. Vitiligo: to biopsy or not to biopsy. Cutis, vol:105(4), pp.189-190. 2020

[7] J., Howitz, H., Brodthagen, M., Schwartz, and K.Thomsen,. Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol, vol:113(1),pp. 47-52. 1977

[8] K., Ezzedine, V., Eleftheriadou, M., Whitton, and N.. van Geel, Vitiligo. Lancet, vol:386(9988), pp.74-84. 2015

[9] S. W., Henning, D., Jaishankar, L. W., Barse, , E. R., Dellacecca N., Lancki, K., Webb, L., Janusek, H. L., Mathews, R. N., Jr., Price, and I. C. Le Poole, The relationship between stress and vitiligo: Evaluating perceived stress and electronic medical record data. PLoS One, vol:15(1), e0227909. 2020

[10] M., Picardo, M. L., Dell'Anna, K., Ezzedine, I., Hamzavi, J. E., Harris, D., Parsad, and A. Taieb, Vitiligo. Nat Rev Dis Primers, 1, vol:15011. 2015.

[11] I., Kaur, and A. Singal, Definition, Epidemiology, and Prevalence. In Comprehensive Textbook on Vitiligo (pp. 7-8): CRC Press. 2020.

[12] R. A., Spritz, and G. H. Andersen, Genetics of Vitiligo. Dermatol Clin, vol :35(2), pp.245-255. (2017).

[13] N Hlača,., T Žagar,., M Kaštelan,., I Brajac,., and Prpić-Massari, L.. Current Concepts of Vitiligo Immunopathogenesis. Biomedicines, vol :10(7), pp .1639(2022).

[14] R Speeckaert,., J Dugardin,., J Lambert,., H Lapeere,., E Verhaeghe,., M. M Speeckaert,., and van Geel, N.. Critical appraisal of the oxidative stress pathway in vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol, vol:32(7), pp.1089-1098(2018).

[15] R. Y. Wagner,., F Luciani,., M. Cario-André,., A. Rubod,., V. Petit,., L Benzekri,., K Ezzedine,., S Lepreux,., E Steingrimsson,., A Taieb,., Y Gauthier,., L Larue,., and V Delmas,.). Altered E-Cadherin Levels and Distribution in Melanocytes Precede Clinical Manifestations of Vitiligo. J Invest Dermatol, vol:135(7), pp.1810-1819(2015.

[16] H. Z Marchioro,., C. C. S. d Castro,., V. M Fava,., P. H Sakiyama,., G Dellatorre,., and H Miot,. A.. Update on the pathogenesis of vitiligo. An Bras Dermatol, vol:97, pp.478-490(2022).

[17] M. A El-Gayyar,., M. E Helmy,., E. R Amer,., M. A Elsaied,., and M. A Gaballah,. (Antimelanocyte antibodies: A possible role in patients with vitiligo. Indian J Dermatol, vol:65(1), pp.33(2020)..

[18] D. S Annan,. Assessment of thiol level in cases of Non-segmental vitiligo. Int. J. Dermatol. Venereol. Lepr. Sci,vol: 2, pp.10-12(2019).

[19] N van Geel,., and R Speeckaert,. Segmental vitiligo. Dermatol Clin,vol. 35(2),pp. 145-150(2017)..

[20] E Nicolaidou,., S Mastraftsi,., V Tzanetakou,., and D Rigopoulos,. Childhood vitiligo. Am J Clin Dermatol, vol:20(4),pp. 515-526(2019)..

[21] R Dimova,., and T Tankova,. The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis. Biomed Res Int, vol:2015,pp. 823481(2015).

[22] I Kyrou,., H. S Mattu,., K Chatha,., and H. S Randeva,.. Chapter 7 - Fat Hormones, Adipokines. In J. C. Schisler, C. H. Lang, and M. S. Willis (Eds.), Endocrinology of the Heart in Health and Disease (pp. 167-205): Academic Press(2017)..

[23] J. C Schisler,., C. H Lang,., and M Willis,. Endocrinology of the Heart in Health and Disease: Integrated, Cellular, and Molecular Endocrinology of the Heart (Vol. 98): Academic Press(2016)..

[24] P Kiluk,., A Baran,., T. W Kaminski,., M Maciaszek,., and I Flisiak,. Decreased levels of vaspin and its potential association with cardiometabolic risk in patients with psoriasis: preliminary results. Postepy Dermatol Alergol,vol: 39(2),pp. 307-315(2022).

[25] K Zorena,., O Jachimowicz-Duda,., D Ślęzak,., M Robakowska,., and M Mrugacz,. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int J Mol Sci, vol:21(10),pp. 3570(2020).

[26] S Phalitakul, M Okada, Y Hara, Yamawaki H. Vaspin prevents TNF-a-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-kB and PKCq activation in cultured rat vascular smooth muscle cells. Pharmacol Res;vol:64:493–pp.5002011.

[27] GF Mohammed, AH Gomaa, MS Al-Dhubaibi. Highlights in pathogenesis of vitiligo. World J Clin Cases;vol:3:221pp.–302015.

[28] A Zhernakova, CC Van Diemen, C Wijmenga. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet.;vol:10(1):43pp.–552009

[29] M Carlström, AK Ekman, S Petersson, P Söderkvist, C Enerbäck. Genetic support for the role of the NLRP3 infammasome in psoriasis susceptibility. Exp Dermatol.;vol:21(12)pp.:932–72012.

[30] J Marie, D Kovacs, C Pain, T Jouary, C Cota, B Vergier, et al. Infammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol.;vol:170(4):pp.816–23(2014).

[31] K Sandhu, I Kaur, B Kumar. Psoriasis and vitiligo. J Am Acad Dermatol.;vol:51(1):pp.149–502004.